Mitra Biotech Private Ltd. is a translational biology company focused on enabling rational drug discovery and personalized cancer care through our preclinical platform CANScript™.
Founded in 2009 as an MIT/ Harvard spinoff, Mitra Biotech is an Indian-American venture (funded by some of the major global venture capital firms). Our aim is to become a partner of choice to global pharmaceutical and biotech companies. We want to support their oncology based new drug development as they navigate from late discovery to preclinical and clinical stages.
Our preclinical platform CANScript™ enables personalized cancer care by selecting the optimal drug or drug combination for a given patient under investigation. Besides, we have developed substantiated know-how for generating orthotopic and sub-cutaneous xenograft mouse models using primary, refractory and metastatic human tumors. Mitra Biotech has a tumor bank with over 600 viable, refractory tumors in early passage (up to 3) with annotated data. We further have a 5,000 Sq Ft Wet Laboratory and a 15,000Sq Ft leased AAALAC Facility where 30 scientists with proven track record of drug discovery and development in leading pharma companies, contribute to continuous research and validation of CANScript™.
Mitra Biotech has partnered some of the leading Indian and American Cancer Hospitals such as - Tata Memorial Hospital
- Mazumdar-Shaw Cancer Centre
- HCG Cancer Care Network
We look forward to partner more hospitals and pharma companies thereby making treatment a discovery research robust and affordable.